157 related articles for article (PubMed ID: 37569447)
1. Adaptation of the Th-MYCN Mouse Model of Neuroblastoma for Evaluation of Disseminated Disease.
Rahavi SM; Aletaha M; Farrokhi A; Lorentzian A; Lange PF; Maxwell CA; Lim CJ; Reid GSD
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569447
[TBL] [Abstract][Full Text] [Related]
2. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.
Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106
[TBL] [Abstract][Full Text] [Related]
3. miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.
Terrile M; Bryan K; Vaughan L; Hallsworth A; Webber H; Chesler L; Stallings RL
PLoS One; 2011; 6(12):e28356. PubMed ID: 22164278
[TBL] [Abstract][Full Text] [Related]
4. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.
Althoff K; Beckers A; Bell E; Nortmeyer M; Thor T; Sprüssel A; Lindner S; De Preter K; Florin A; Heukamp LC; Klein-Hitpass L; Astrahantseff K; Kumps C; Speleman F; Eggert A; Westermann F; Schramm A; Schulte JH
Oncogene; 2015 Jun; 34(26):3357-68. PubMed ID: 25174395
[TBL] [Abstract][Full Text] [Related]
5.
McNerney KO; Karageorgos S; Ferry GM; Wolpaw AJ; Burudpakdee C; Khurana P; Toland CN; Vemu R; Vu A; Hogarty MD; Bassiri H
Oncoimmunology; 2022; 11(1):2075204. PubMed ID: 35646475
[TBL] [Abstract][Full Text] [Related]
6. Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis.
Teitz T; Inoue M; Valentine MB; Zhu K; Rehg JE; Zhao W; Finkelstein D; Wang YD; Johnson MD; Calabrese C; Rubinstein M; Hakem R; Weiss WA; Lahti JM
Cancer Res; 2013 Jul; 73(13):4086-97. PubMed ID: 23536557
[TBL] [Abstract][Full Text] [Related]
7. Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.
Rasmuson A; Segerström L; Nethander M; Finnman J; Elfman LH; Javanmardi N; Nilsson S; Johnsen JI; Martinsson T; Kogner P
PLoS One; 2012; 7(12):e51297. PubMed ID: 23284678
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.
Chen L; Esfandiari A; Reaves W; Vu A; Hogarty MD; Lunec J; Tweddle DA
Int J Oncol; 2018 Mar; 52(3):967-977. PubMed ID: 29393340
[TBL] [Abstract][Full Text] [Related]
9. Molecular imaging of neuroblastoma progression in TH-MYCN transgenic mice.
Quarta C; Cantelli E; Nanni C; Ambrosini V; D'ambrosio D; Di Leo K; Angelucci S; Zagni F; Lodi F; Marengo M; Weiss WA; Pession A; Tonelli R; Fanti S
Mol Imaging Biol; 2013 Apr; 15(2):194-202. PubMed ID: 22777578
[TBL] [Abstract][Full Text] [Related]
10. Immune characterization of pre-clinical murine models of neuroblastoma.
Webb ER; Lanati S; Wareham C; Easton A; Dunn SN; Inzhelevskaya T; Sadler FM; James S; Ashton-Key M; Cragg MS; Beers SA; Gray JC
Sci Rep; 2020 Oct; 10(1):16695. PubMed ID: 33028899
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma.
Jamin Y; Tucker ER; Poon E; Popov S; Vaughan L; Boult JK; Webber H; Hallsworth A; Baker LC; Jones C; Koh DM; Pearson AD; Chesler L; Robinson SP
Radiology; 2013 Jan; 266(1):130-40. PubMed ID: 23169794
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Proteomics of Th-MYCN Transgenic Mice Reveals Aurora Kinase Inhibitor Altered Metabolic Pathways and Enhanced ACADM To Suppress Neuroblastoma Progression.
Hsieh CH; Cheung CHY; Liu YL; Hou CL; Hsu CL; Huang CT; Yang TS; Chen SF; Chen CN; Hsu WM; Huang HC; Juan HF
J Proteome Res; 2019 Nov; 18(11):3850-3866. PubMed ID: 31560547
[TBL] [Abstract][Full Text] [Related]
13. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
Rounbehler RJ; Li W; Hall MA; Yang C; Fallahi M; Cleveland JL
Cancer Res; 2009 Jan; 69(2):547-53. PubMed ID: 19147568
[TBL] [Abstract][Full Text] [Related]
14. Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents.
Kroesen M; Brok IC; Reijnen D; van Hout-Kuijer MA; Zeelenberg IS; Den Brok MH; Hoogerbrugge PM; Adema GJ
Cancer Immunol Immunother; 2015 May; 64(5):563-72. PubMed ID: 25687736
[TBL] [Abstract][Full Text] [Related]
15. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression.
Hagemann S; Misiak D; Bell JL; Fuchs T; Lederer MI; Bley N; Hämmerle M; Ghazy E; Sippl W; Schulte JH; Hüttelmaier S
Mol Cancer; 2023 May; 22(1):88. PubMed ID: 37246217
[TBL] [Abstract][Full Text] [Related]
16. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS
J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228
[TBL] [Abstract][Full Text] [Related]
17. Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.
Waldeck K; Cullinane C; Ardley K; Shortt J; Martin B; Tothill RW; Li J; Johnstone RW; McArthur GA; Hicks RJ; Wood PJ
Int J Cancer; 2016 Jul; 139(1):194-204. PubMed ID: 26914605
[TBL] [Abstract][Full Text] [Related]
18. Nanomicellar Lenalidomide-Fenretinide Combination Suppresses Tumor Growth in an
Orienti I; Farruggia G; Nguyen F; Guan P; Calonghi N; Kolla V; Chorny M; Brodeur GM
Int J Nanomedicine; 2020; 15():6873-6886. PubMed ID: 32982239
[TBL] [Abstract][Full Text] [Related]
19. Expression of programmed cell death-1 on neuroblastoma cells in TH-MYCN transgenic mice.
Takeuchi Y; Inoue S; Odaka A
Pediatr Surg Int; 2022 Nov; 39(1):6. PubMed ID: 36441248
[TBL] [Abstract][Full Text] [Related]
20. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
